Delhi HC Seeks Response From Govt, NPPA On Glenmark’s Plea

New Delhi: Glenmark Pharma on Tuesday moved the Delhi High Court, seeking setting aside the National Pharmaceutical Pricing Authority’s standing order that fixed a lower retail price than the launched price of its anti-diabetic drug formulations comprising Remogliflozin + Vildagliptin + Metformin.

The pharma firm termed the retail price of Rs. 8.76 per tablet and Rs. 9.06 per tablet, respectively, excluding GST, as illegal and arbitrary. It also claimed that its formulations are “new drugs” approved by the Drugs Controller General of India (DCGI) and are exempt from the Drugs (Pricing and Control) Order, 2013.

Justice Subramonium Prasad sought response from the Ministry of Chemicals and Fertilisers and the National Pharmaceutical Pricing Authority (NPPA) ) on the Glenmark’s petition which also sought the quashing of notices, decisions and standing order issued taken by the authority against it for selling the formulations comprising of “Remo MV” ‘Remogliflozin Etabonate 100 mg + Vildagliptin 50 mg + Metformin Hydrochloride IP 500 mg Tablets’ and ‘Remogliflozin Etabonate 100 mg + Vildagliptin 50mg + Metformin Hydrochloride IP 1000 mg Tablets’, without obtaining prior price approval under the 2013 Order.

Senior counsel Arvind Nigam and counsel Debmalya Banerjee and Rohan Sharma argued that these formulations being “new drugs” within the meaning of Rule 122E of the Drugs and Cosmetics Rules, 1945 (DCR), have been approved by the Drugs Controller General of India (DCGI) and were commercially launched under a valid patent granted under the Patents Act, 1970.

According to the counsel, the NPPA has proceeded on the basis of an “arbitrary and erroneous interpretation” that the exemption under paragraph 32 of the DPCO 2013 cannot be “self-invoked” and instead required Glenmark to obtain an exemption from the former in respect of its formulations.

“No procedure has been prescribed for availing the exemption under paragraph 32 of the DPCO 2013 or under any other guidelines, directions or office memorandum by NPPA, the petition stated, adding that the government could not have proceeded to issue notices and fix prices, without any authority or jurisdiction and also in violation of principles of natural justice as the decisions have been taken without giving any hearing to the pharma firm.

Similar notices issued to other homegrown pharma majors like , Abbott Healthcare, Sun Pharma Labs and others are also under challenge before the HC.

Related Posts

  • Pharma
  • May 25, 2024
  • 64 views
NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of asthma inhaler drug combination formoteral 6 mcg and budesonide 400 mcg dry power inhaler (DPI) under…

  • Pharma
  • May 25, 2024
  • 75 views
Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Jaipur: To provide quality education in pharmacy institutes, the central government has prepared to end the duplicate system. Strict action will be taken against fake students and teachers in newly opened…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

A Doctor diagnoses Mood of Voters in Delhi

A Doctor diagnoses Mood of Voters in Delhi

NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Tripura Police Seized Banned Cough Syrup Worth Rs 30 Lakh In Dhalai; One Arrested

Tripura Police Seized Banned Cough Syrup Worth Rs 30 Lakh In Dhalai; One Arrested

Ex-Pharmacy Council Registrar Gave Certificates To Ineligible Candidates?

Ex-Pharmacy Council Registrar Gave Certificates To Ineligible Candidates?

Experts Call For Ethical Standards, Patient Advocacy In Clinical Research

Experts Call For Ethical Standards, Patient Advocacy In Clinical Research